Induction chemotherapy for unresectable urothelial carcinoma of the bladder

Study Type – Therapy (case series) Level of Evidence 4

[1]  H. Grossman,et al.  Commentary on A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience , 2009 .

[2]  E. Klein,et al.  Lack of pathologic down‐staging with neoadjuvant chemotherapy for muscle‐invasive urothelial carcinoma of the bladder , 2009, Cancer.

[3]  P. Russo,et al.  A role for neoadjuvant gemcitabine plus cisplatin in muscle‐invasive urothelial carcinoma of the bladder , 2008, Cancer.

[4]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[5]  M. Dimopoulos,et al.  Neoadjuvant chemotherapy in invasive bladder cancer , 2005, Expert review of anticancer therapy.

[6]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[7]  J. Montie.  Is eligibility for a chemotherapy protocol a good prognostic factor for invasive bladder cancer after radical cystectomy? , 2005, Journal of Urology.

[8]  M. Parmar,et al.  Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. , 2005, European urology.

[9]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[10]  F. Burkhard,et al.  Radical cystectomy for bladder cancer today--a homogeneous series without neoadjuvant therapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.